APOE and COVID-19: Recent analyses have also shown that homozygosity for ApoE4 was associated with significantly higher risk of SARS-CoV-2 infection as well as mortality from COVID-19, even after exclusion of subjects with potential confounding comorbidities, such as dementia, hypertension, type 2 diabetes, or CAD (33, 34).